It’s been just over two years since INC Research and inVentiv came together in a $7.4 billion merger and rebranded as Syneos Health. Now, it’s looking for a sale.
That’s according to “people familiar with the matter” speaking anonymously to Reuters this week, who add that the North Carolina CRO is working with investment bank Centerview Partners “on soliciting acquisition offers from other companies and private equity firms.”
The CRO had been trading down—like almost every public company due to the coronavirus volatility—but was up by $10 a share on the Reuters report March 9, although it was back in the red in trading Tuesday. Its market cap is around $6.4 billion.
The CRO was not commenting on the story.
By Ben Adams
Source: Fierce Biotech
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.